IL149705A0 - Combination treatment for depression and anxiety - Google Patents

Combination treatment for depression and anxiety

Info

Publication number
IL149705A0
IL149705A0 IL14970502A IL14970502A IL149705A0 IL 149705 A0 IL149705 A0 IL 149705A0 IL 14970502 A IL14970502 A IL 14970502A IL 14970502 A IL14970502 A IL 14970502A IL 149705 A0 IL149705 A0 IL 149705A0
Authority
IL
Israel
Prior art keywords
anxiety
depression
combination treatment
treatment
combination
Prior art date
Application number
IL14970502A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL149705A0 publication Critical patent/IL149705A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14970502A 2001-05-23 2002-05-16 Combination treatment for depression and anxiety IL149705A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29306301P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
IL149705A0 true IL149705A0 (en) 2002-11-10

Family

ID=23127491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14970502A IL149705A0 (en) 2001-05-23 2002-05-16 Combination treatment for depression and anxiety

Country Status (10)

Country Link
EP (1) EP1260221A3 (enExample)
JP (1) JP2002370976A (enExample)
KR (1) KR20020090152A (enExample)
CN (1) CN1386504A (enExample)
AU (1) AU4068102A (enExample)
CA (1) CA2386287A1 (enExample)
HU (1) HUP0201720A2 (enExample)
IL (1) IL149705A0 (enExample)
PL (1) PL354111A1 (enExample)
ZA (1) ZA200204018B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514675A (pt) * 2004-09-10 2008-06-17 Pfizer Prod Inc ligantes de éter difenìlico terapêuticos
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
US8609162B2 (en) * 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN118116616A (zh) * 2024-01-17 2024-05-31 北京大学第六医院 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者治疗产生不良反应及指导用药的装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
ES2139750T3 (es) * 1993-08-06 2000-02-16 Upjohn Co 2-aminoindanos como ligandos selectivos d3 de la dopamina.
WO1996023760A1 (en) * 1995-02-01 1996-08-08 Pharmacia & Upjohn Company 2-aminoindans as selective dopamine d3 ligands
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
YU56301A (sh) * 1999-02-23 2004-05-12 Pfizer Products Inc. Inhibitori resorpcije monoamina za tretiranje poremećaja cns

Also Published As

Publication number Publication date
PL354111A1 (en) 2002-12-02
CN1386504A (zh) 2002-12-25
EP1260221A2 (en) 2002-11-27
CA2386287A1 (en) 2002-11-23
AU4068102A (en) 2002-12-05
JP2002370976A (ja) 2002-12-24
HUP0201720A2 (hu) 2003-07-28
HU0201720D0 (enExample) 2002-07-29
ZA200204018B (en) 2003-11-21
EP1260221A3 (en) 2002-12-18
KR20020090152A (ko) 2002-11-30

Similar Documents

Publication Publication Date Title
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
GB0111872D0 (en) Therapeutic agents and methods
GB0116247D0 (en) Surgical techniques and devices
EP1558321A4 (en) MASK AND ASSOCIATED COMPONENTS
GB0115980D0 (en) Apparatus and methods
GB0110288D0 (en) Composition and treatment method
EP1434772A4 (en) CONNECTIONS AND METHODS
PL369288A1 (en) Catheter and use method thereof
IL154553A0 (en) Urocortin-iii and uses thereof
AU2002359694A8 (en) Compounds and methods
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0102403D0 (en) Hair Treatment Device
HUP0402298A3 (en) Use of desoxypeganine for treating clinical depression
ZA200204018B (en) Combination treatment for depression and anxiety.
AU5565401A (en) Materials and methods for the treatment of depression
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
GB0130763D0 (en) Treatment methods
EP1379240A4 (en) CONNECTIONS AND METHODS
GB0120612D0 (en) Method and device
EP1367123A4 (en) NEUROTONIN AND ITS USE
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
GB2377179B (en) Magnotherapy device and use thereof
GB0112237D0 (en) Compounds and their therapeutic use
GB0112236D0 (en) Compounds and their therapeutic use
GB0130694D0 (en) Treatment